2026 Binaytara Dallas Conference: Cellular Therapies for Cancer and Beyond – The Next Frontier
Accreditation: 6.25 AMA PRA Category 1 Credit™ | 6.25 Nursing Contact Hours | 6.25 ACPE Pharmacy | 6.25 ABIM MOC II
Venue: Crown Plaza Dallas Downtown by IHG, 1015 Elm Street, Dallas, TX, United States
Official conference page for 2026 Binaytara Dallas Conference: Cellular Therapies for Cancer and Beyond – The Next Frontier. https://binaytara.org/projects/conferences/2026-cellular-therapy-conference-dallas
About 2026 Binaytara Dallas Conference: Cellular Therapies for Cancer and Beyond – The Next Frontier


Faculty and committee
Our Speakers
Planning Committee
Faculty
Conference program and agenda
Our Agenda
Saturday, April 25th, 2026
All timings are in Central Time (CDT, GMT-05:00) time.
Session Chair: Praveen Ramakrishnan Geethakumari, MD, MBA
08:25 AM - 08:45 AM
Updates in CAR T-cell therapy for Aggressive Lymphomas (DLBCL, MCL): SOC and Emerging Constructs – Elif Yilmaz, MD
08:45 AM - 09:05 AM
CAR T-Cell Therapy in Indolent Lymphomas (FL) and CLL/SLL – Bradley Christensen, MD
09:05 AM - 09:25 AM
Role for Stem cell Transplantation and Emerging Cellular Therapies in T-cell Lymphomas (PTCL and CTCL) – Swaminathan Padmanabhan Iyer, MD
09:25 AM - 09:40 AM
Panel Discussion – Moshe Yair Levy, MD; Elif Yilmaz, MD; Bradley Christensen, MD; Swaminathan Padmanabhan Iyer, MD
Session Chair: Nebu Koshy, MD; John Mathews, MD
09:55 AM - 10:15 AM
How to best incorporate CAR T in Adult ALL? – Vivian Irizarry Gatell, MD
10:15 AM - 10:35 AM
Emerging Cellular Therapies and Role of Allogeneic SCT in AML – Clayton Jackson, MD
10:35 AM - 10:50 AM
Panel Discussion – Vivian Irizarry Gatell, MD; Clayton Jackson, MD
10:50 AM - 11:15 AM
What to Expect for the Next Decade in Cellular Therapies? – Sattva S Neelapu, MD
11:15 AM - 11:30 AM
Q&A
Session Chair: Robert Brian Berryman, MD; Larry D. Anderson, MD, PhD, FACP
12:30 PM - 12:50 PM
Emerging Role of Auto Stem Cell Transplantation in Multiple Myeloma: For All or for Some? – Adeel Khan, MD, MS, MPH
12:50 PM - 01:10 PM
Optimal Timing of CAR T-Cell Therapy in Multiple Myeloma: Current Evidence and Future Directions – Aimaz Afrough, MD
01:10 PM - 01:30 PM
Immunotherapy for Relapsed Multiple Myeloma: CAR T-Cell Therapy or Bispecific Antibodies First? – Sean Maximillian Taasan, MD
01:30 PM - 01:45 PM
Panel Discussion – Samer Al Hadidi, MD; Adeel Khan, MD, MS, MPH; Aimaz Afrough, MD; Sean Maximillian Taasan, MD
Session Chair: Richard T. Maziarz, MD
01:45 PM - 02:05 PM
Identificaton and Management of CAR T-related Toxicities – John Mathews, MD
02:05 PM - 02:25 PM
From Community Oncology to CAR T-centers and back: Navigating Brain-to-vein time, Logistics and Survivorship – Carolina Escobar, MD
02:25 PM - 02:45 PM
Improving Accessibility and Sustainability of Cellular Therapy – Richard T. Maziarz, MD
02:45 PM - 03:00 PM
Panel Discussion – John Mathews, MD; Carolina Escobar, MD
Session Chair: Luis Pineiro, MD
03:20 PM - 03:40 PM
Immunotherapy for Rheumatologic and other Autoimmune Diseases: Current Evidence and Future Directions – Luis Pineiro, MD
03:40 PM - 04:00 PM
Gene Therapies for SCD, Thalassemia and Beyond – Jean-Antoine Ribeil, MD, PhD
04:00 PM - 04:20 PM
Cellular Therapy for Solid Tumors – Jaehyuk Choi, MD, PhD
